The effect of combined β2-agonist and anticholinergic inhaled therapy in patients with COPD Source: Eur Respir J 2004; 24: Suppl. 48, 341s Year: 2004
Protective effect of inhaled glucocorticosteroid and long-acting beta2-agonist combination on COPD model Source: Virtual Congress 2021 – Developments in biomarkers and treatment strategies for chronic lung diseases Year: 2021
Anti-inflammatory therapy COPD: fenspiride and(or) theophylline versus inhaled corticosteroids? Source: Annual Congress 2007 - Treatment of COPD Year: 2007
The effects of nebulised bronchodilators and corticosteroids treatment compared with inhaled drug therapy for moderate COPD patients Source: Eur Respir J 2004; 24: Suppl. 48, 290s Year: 2004
The anti-tussive effects of an inhaled LABA are maintained after chronic treatment Source: International Congress 2018 – Preclinical pharmacology: novel targets in airway inflammation, narrowing and neural control Year: 2018
Oral steroid-sparing effect of high-dose inhaled corticosteroids in asthma Source: Eur Respir J, 55 (1) 1901147; 10.1183/13993003.01147-2019 Year: 2020
Protective effect of inhaled glucocorticosteroids on COPD model. Source: Virtual Congress 2020 – Mechanistic insight into lung injury and repair Year: 2020
Anti-inflammatory effects of add-on atorvastatin therapy during the treatment of COPD patients Source: Annual Congress 2012 - Trials in COPD: novel treatments and insights Year: 2012
Effects of a single inhaled budesonide/formoterol dose on glucocorticoid receptor activity in sputum of COPD patients Source: International Congress 2016 – Novel insights into the treatment of COPD Year: 2016
Concomitant use of low-dose inhaled corticosteroids and a long-acting bronchodilatator visavi doubling the dose of inhaled corticosterod in asthma patients Source: Eur Respir J 2001; 18: Suppl. 33, 98s Year: 2001
Persistency of antioxidant/antiinflammatory effects of erdosteine treatment in COPD Source: Annual Congress 2009 - Drug effects in COPD Year: 2009
Treatment of COPD: comparing the effects of inhaled steroids with N-acetylcysteine Source: Eur Respir J 2005; 26: Suppl. 49, 295s Year: 2005
Efficacy and safety of high-dose inhaled corticosteroids therapy in children with asthma Source: Annual Congress 2010 - Allergy and risk factors in paediatrics Year: 2010
The effects of addition montelukast to inhaled steroids in the regular treatment of asthma Source: Eur Respir J 2001; 18: Suppl. 33, 262s Year: 2001
The effects of adding in erdosteine on the routine bronchodilator therapy in moderate and severe COPD patients Source: Annual Congress 2006 - COPD therapy Year: 2006
The impact of tiotropium on mortality when added to inhaled corticosteroids and long-acting beta agonist therapy in COPD Source: Annual Congress 2011 - Bronchodilators in asthma and COPD Year: 2011
Reducing the dose of inhaled corticosteroids (ICS) under therapy with montelukast in stable asthma: effects on lung function and inflammation Source: Eur Respir J 2001; 18: Suppl. 33, 261s Year: 2001
Effects of montelukast on tapering inhaled corticosteroids in patients with asthma Source: Eur Respir J 2001; 18: Suppl. 33, 260s Year: 2001
Effects of montelukast on tapering inhaled corticosteroids in patients with asthma Source: Eur Respir J 2002; 20: Suppl. 38, 407s Year: 2002
lnhaled long-acting beta-agonists as an inhaled corticosteroid-sparing agent for chronic asthma in adults Source: Eur Respir J 2005; 26: Suppl. 49, 124s Year: 2005